스코폴라민 시장 : 제형, 용도, 투여 경로, 유통 채널별 - 세계 예측(2024-2032년)

Global Scopolamine Market will witness 5.3% CAGR between 2024 and 2032, fueled by increasing collaborative research in the field. Scopolamine, an anticholinergic drug used primarily for its antiemetic and anticholinergic properties, is seeing heightened interest due to its potential applications beyond traditional uses. Collaborative research among pharmaceutical companies, academic institutions, and research organizations is expanding the understanding of Scopolamine's efficacy and safety in treating various conditions, including motion sickness, postoperative nausea, and even certain neurological disorders.

These research efforts are leading to new clinical trials, innovative formulations, and enhanced delivery systems, driving market growth. The integration of multidisciplinary approaches in studying Scopolamine's mechanisms and therapeutic benefits is accelerating the development of advanced treatments. As these collaborations yield promising results, the market is experiencing increased demand for scopolamine-based therapies, reflecting the broader trend of leveraging joint expertise to advance medical treatments and improve patient outcomes.

The overall Scopolamine Industry value is classified based on the dosage form, application, route of administration, distribution channel, and region.

Based on dosage form, the scopolamine market revenue from the tablets segment will register a commendable CAGR from 2024 to 2032. Tablets offer a convenient and precise dosage form, enhancing patient compliance and ease of use. Scopolamine tablets, known for their effectiveness in treating motion sickness and postoperative nausea, provide a non-invasive alternative to other delivery methods. The growing preference for oral medications, coupled with advancements in tablet technology, is driving market growth. Tablets' extended shelf life and stability further contribute to their appeal. As consumers and healthcare providers seek reliable and user-friendly treatment options, the demand for scopolamine tablets continues to rise.

In terms of application, the postoperative nausea segment will witness an appreciable growth from 2024 to 2032. This condition, a common complication following surgical procedures, significantly impacts patient comfort and recovery. Scopolamine, with its anticholinergic properties, provides effective relief from nausea and vomiting, making it a valuable option for postoperative care. Its ability to be administered in various forms, including patches and tablets, enhances its versatility and appeal. As healthcare providers focus on improving postoperative patient outcomes, the demand for Scopolamine as a reliable treatment for managing postoperative nausea continues to rise, supporting its market growth.

Europe Scopolamine market will exhibit a notable CAGR from 2024 to 2032. European healthcare providers and patients increasingly seek effective and non-invasive treatment options, boosting Scopolamine's popularity. The availability of various formulations, such as patches and tablets, enhances patient compliance and accessibility. Additionally, increased awareness and research into Scopolamine's benefits contribute to its rising demand. European regulatory approvals and clinical studies further support market expansion. As the focus on patient comfort and effective symptom management intensifies, Scopolamine's role in the European healthcare landscape continues to grow.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing number of surgical procedures due to chronic diseases
    • 3.2.1.2 Advancements in drug delivery systems
    • 3.2.1.3 Increasing prevalence of motion sickness and nausea
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and safety concerns
    • 3.2.2.2 Availability of alternative therapies
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
  • 3.6.1 Core technologies
  • 3.6.2 Adjacent technologies
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Transdermal patches
• 5.3 Tablets
• 5.4 Injectables
• 5.5 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Motion sickness
• 6.3 Postoperative nausea and vomiting (PONV)
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Topical
• 7.3 Oral
• 7.4 Parenteral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alchem International Pvt. Ltd.
• 10.2 Australian Alkaloids Ltd.
• 10.3 Baxter International Inc.
• 10.4 Caleb Pharmaceuticals, Inc.
• 10.5 Fine Chemicals Corporation
• 10.6 Fresenius SE & Co. KGaA
• 10.7 GSK plc
• 10.8 Ingenus Pharmaceuticals
• 10.9 Mylan N.V.
• 10.10 Myungmoon Pharm. Co., Ltd.
• 10.11 Novartis AG
• 10.12 Perrigo Company plc
• 10.13 Pfizer Inc.
• 10.14 Phytex Australia
• 10.15 Teva Pharmaceutical Industries Limited